Perampanel

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Idiopathic Generalized Epilepsy

Conditions

Idiopathic Generalized Epilepsy, Partial Onset Seizures, Generalised Tonic-Clonic Seizures

Trial Timeline

Jul 20, 2020 → Jan 12, 2023

NCT ID

NCT04252846

About Perampanel

Perampanel is a pre-clinical stage product being developed by Eisai for Idiopathic Generalized Epilepsy. The current trial status is completed. This product is registered under clinical trial identifier NCT04252846. Target conditions include Idiopathic Generalized Epilepsy, Partial Onset Seizures, Generalised Tonic-Clonic Seizures.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01871233	Pre-clinical	Completed	—	—	Partial Onset Seizures
NCT02307578	Pre-clinical	Completed	—	—	Primary Generalized Tonic-Clonic or Partial Onset Seizures
NCT05533814	Approved	Completed	Oct 19, 2022	Jan 23, 2025	Epilepsy
NCT04252846	Pre-clinical	Completed	Jul 20, 2020	Jan 12, 2023	Idiopathic Generalized Epilepsy
NCT03836924	Pre-clinical	Completed	Feb 18, 2019	Mar 1, 2020	Partial Onset Seizures
NCT03424564	Phase 1	Completed	Mar 20, 2018	May 25, 2018	Healthy Subjects
NCT03288129	Approved	Completed	Aug 23, 2017	Apr 27, 2021	Partial Onset Seizures
NCT02914314	Phase 2	Completed	Feb 20, 2017	Apr 25, 2023	Epilepsy
NCT02849626	Phase 3	Completed	Nov 16, 2016	Dec 6, 2021	Partial-Onset or Primary Generalized Tonic-Clonic Seizures
NCT02726074	Approved	Completed	May 3, 2016	Apr 26, 2018	Epilepsy
NCT04230044	Pre-clinical	Completed	Apr 11, 2016	Jul 3, 2017	Epilepsy
NCT04257604	Pre-clinical	Completed	Jan 3, 2016	Apr 30, 2019	Partial Seizures
NCT02727101	Approved	Terminated	Nov 1, 2015	Jul 1, 2017	Epilepsy
NCT02427607	Phase 3	Completed	May 12, 2015	Nov 9, 2016	Epilepsy
NCT02279485	Phase 1	Completed	Sep 1, 2014	Jan 1, 2015	Healthy Subjects
NCT02033902	Pre-clinical	Completed	Jun 6, 2014	Jan 31, 2018	Epilepsy
NCT01527006	Phase 2	Completed	Jan 1, 2012	Apr 1, 2015	Central Nervous System
NCT00903786	Phase 2	Completed	Jun 17, 2009	Oct 31, 2016	Refractory Partial Seizures
NCT00735397	Phase 3	Completed	Oct 1, 2008	Sep 1, 2014	Epilepsy
NCT00505622	Phase 3	Terminated	Jul 1, 2007	Apr 1, 2008	Parkinson's Disease

Competing Products

20 competing products in Idiopathic Generalized Epilepsy

See all competitors

Product	Company	Stage	Hype Score
KPL-716 + Placebo	Kiniksa Pharmaceuticals	Phase 2	47
Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) + Placebo	Rein Therapeutics	Phase 1	25
LTI-03 + Placebo	Rein Therapeutics	Phase 1	25
LTI-03 + Placebo	Rein Therapeutics	Phase 2	44
Tirzepatide + Tirzepatide Placebo	Eli Lilly	Approved	85
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	77
MRA(Tocilizumab) + placebo	Chugai Pharmaceutical	Phase 3	77
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	77
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	77
Zimura + Eylea	Astellas Pharma	Phase 2	52
Avacincaptad Pegol	Astellas Pharma	Phase 2	52
Rituximab + cyclosporine	Sun Pharmaceutical	Phase 3	77
E5501	Eisai	Phase 1	33
E5501 + Drug: E5501	Eisai	Phase 1	33
E5501 40 mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with food + E5501 40mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with food	Eisai	Phase 1	33
Eltrombopag + Avatrombopag + Standard of care	Eisai	Phase 3	77
Placebo + Avatrombopag tablets	Eisai	Phase 2	52
Blinded (placebo) + Open Label (Avatrombopag tablets) + Blinded (Avatrombopoag tablets)	Eisai	Phase 2	52
Istradefylline 20 mg or 40 mg	Kyowa Kirin	Phase 3	77
10-mg dose of E5501 2G tablet + 10-mg dose of E5501 cyclodextrin oral solution + 10-mg dose of E5501-P21% powder + 10-mg dose of E5501 lipid-based oral	Eisai	Phase 1	33

Other Products from Eisai

MecobalaminApproved

MonteplaseApproved

E2020 + PlaceboApproved

Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved

DonepezilApproved